In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy.

ABSTRACT: Current therapies against hepatitis B virus (HBV) do not reliably cure chronic infection, necessitating new therapeutic approaches. The T cell response can clear HBV during acute infection, and the adoptive transfer of antiviral T cells during bone marrow transplantation can cure patients of chronic HBV infection. To redirect T cells to HBV-infected hepatocytes, we delivered plasmids encoding bispecific antibodies directed against the viral surface antigen (HBsAg) and CD3, expressed on almost all T cells, directly into the liver using hydrodynamic tail vein injection. We found a significant reduction in HBV-driven reporter gene expression (184-fold) in a mouse model of acute infection, which was 30-fold lower than an antibody only recognizing HBsAg. While bispecific antibodies triggered, i

SUBMITTER: Kruse RL 

PROVIDER: S-EPMC5626922 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature